This leaflet answers some common questions about ENERZAIR BREEZHALER. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...